Population Pharmacokinetic Modeling of Standard- and High-Dose Rifampicin for Tuberculosis Preventive Therapy in the 2R2 Randomized Controlled Trial

Key Points

• Higher doses of rifampicin showed non-linear clearance, resulting in increased exposure levels for tuberculosis prevention.
• Greater-than-proportional increases in drug exposure were noted, particularly influenced by country-specific factors.
• Analysis of pharmacokinetic data revealed substantial between-country variability in drug exposure levels.
• Understanding these differences highlights the need for tailored tuberculosis therapy across various populations.